MedPath

e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis

Not Applicable
Completed
Conditions
Psychosis
Interventions
Other: Control
Other: Individual psychoeducation
Registration Number
NCT01783457
Lead Sponsor
Basque Health Service
Brief Summary

Treatment delay in psychosis usually lead to slower recovery, an increase in associated comorbidity and greater deterioration in social and family life of patients. Previous studies indicate that an early intervention with guidelines for increasing adherence to treatment, disease awareness and condition management leads to better progression of the disorder and is therefore related to a better prognosis.

Several studies have found that the rate of relapse is higher in patients with pharmacological treatment alone compared to those also receiving psychoeducation, who tend to improve their adherence to treatment and reduce toxic drugs dosage.

Hypotheses:

* Individual psychoeducation will be effective as complementary therapy to pharmacological treatment in patients with a first psychotic episode, improving disease evolution.

* BDNF levels will increase more in the patients receiving individual therapy compared to those without it.

* Psychoeducation can be performed similarly in all participating centers if the therapists receive the same training and use the same psychoeducation material.

* The use of telemedicine for the follow-up of the patients will help improve the welfare work and therefore the disease evolution.

Detailed Description

Treatment delay in psychosis usually lead to slower recovery, an increase in associated comorbidity and greater deterioration in social and family life of patients. Previous studies indicate that an early intervention with guidelines for increasing adherence to treatment, disease awareness and condition management leads to better progression of the disorder and is therefore related to a better prognosis.

Several studies have found that the rate of relapse is higher in patients with pharmacological treatment alone compared to those also receiving psychoeducation, who tend to improve their adherence to treatment and reduce toxic drugs dosage.

Hypotheses:

* Individual psychoeducation will be effective as complementary therapy to pharmacological treatment in patients with a first psychotic episode, improving the disease evolution.

* BDNF levels will increase more in the patients receiving individual therapy compared to those without it.

* Psychoeducation can be performed similarly in all participating centers if the therapists receive the same training and use the same psychoeducation material.

* The use of telemedicine for the follow-up of the patients will help improve the welfare work and therefore the disease evolution.

Primary Objective:

* To assess the effectiveness of individual psychoeducation together with telemedicine (telephone assistance) as an adjuvant therapy in the pharmacological treatment of patients with first episode psychosis, regarding functionality of patients and positive and negative symptoms.

Secondary Objectives:

* To analyse certain biological parameters (BDNF and oxidative stress) in both arms (intervention and control) at baseline and during re-assessment (at six months and after completion of treatment).

* To analyse the effectiveness of online training of psychotherapists who will provide psychoeducation to patients with first episode psychosis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
177
Inclusion Criteria
  • patients who have suffered a first psychotic episode (diagnosis IV-TR) in the last five years,
  • age between 18 and 45 years,
  • patients who have given written informed consent to participate.
Exclusion Criteria
  • patients with a comorbid disorder that interferes with their ability to communicate,
  • patients who received psychoeducation previous to inclusion in study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlControlUsual treatment
Individual psychoeducationIndividual psychoeducationUsual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
Primary Outcome Measures
NameTimeMethod
Prognosis of patients.6 months

To assess the prognosis of patients by registering the number of relapses and the number of psychiatric hospital admissions.

Secondary Outcome Measures
NameTimeMethod
Score on clinical scales assessing functionality.6 months

To assess the effectiveness of individual psychoeducation together with telemedicine (telephone assistance) as an adjuvant therapy in the pharmacological treatment of patients with first episode psychosis, using different scales for clinical assessment of FUNCTIONALITY (Positive and Negative Syndrome Scale (PANSS), SUMD, Morisky-Green Scale, STAI, Hamilton Rating scale for Depression, LSAS, WHOQOL-BREF, EuroQoL) and PROGNOSIS (Strauss Carpenter Scale, GAF, Functional Assessment Staging Test-FAST).

Score of participating psychotherapists on a specific test after online training.6 months

To analyse the effectiveness of online training of psychotherapist who will provide psychoeducation to patients, all therapists carried out a specific tests after each one of the sessions to confirm if they had delivered the session as specified in the protocol.

Biological Parameters: blood levels of BDNF.6 months

To analyse BDNF biological parameter at baseline and during re-assessment at six months (after completion of treatment): BDNF levels in plasma will be measured by ELISA techniques with a kit based on the Sandwich technique used according to the manufacturer´s instructions (CYT306 from Chemicon). The standard curves will be characterised using plasma duplicates and the absorption determined with a microplate reader (BIO-TEK, Sinergy HT) using a wavelength of 450 nm.

Biological Parameters: levels oxidative stress indicators in blood.6 months

To analyse OXIDATIVE STRESS indicators at baseline and during re-assessment at six months (after completion of treatment): Levels of the following OXIDATIVE STRESS INDICATORS will be measured in red blood cell haemolysates: lipid peroxidation (TBARS), nitrites and superoxide dismutase enzyme, total antioxidant ability, glutathione peroxidase and catalase.

Trial Locations

Locations (6)

Hospital Universitario de Bellvitge

🇪🇸

Hospitalet Llobregat, Barcelona, Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

Universidad del País Vasco

🇪🇸

Bilbao, Vizcaya, Spain

Fundación Clínico Valencia INCLIVA

🇪🇸

Valencia, Spain

Universidad de Valencia

🇪🇸

Valencia, Spain

Araba University Hospital-Santiago

🇪🇸

Vitoria, Álava, Spain

© Copyright 2025. All Rights Reserved by MedPath